Sangamo shares are trading higher after the company entered into a license agreement with Genentech to develop intravenously administered genomic medicines for neurodegenerative diseases. Sangamo is expected to receive $50 million in near-term upfront license fees and is eligible for up to $1.9 billion in milestones.
Portfolio Pulse from Benzinga Newsdesk
Sangamo shares are trading higher after entering a license agreement with Genentech to develop genomic medicines for neurodegenerative diseases. Sangamo will receive $50 million upfront and is eligible for up to $1.9 billion in milestones.
August 06, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo shares are trading higher due to a new license agreement with Genentech, which includes $50 million in upfront fees and potential milestones up to $1.9 billion.
The agreement with Genentech provides Sangamo with immediate financial benefits and significant future revenue potential, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100